Full professor1) Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Norway
Disclosure information not submitted.
Hypothetical target trial to compare the effectiveness of atezolizumab, pembrolizumab and nivolumab in second line treatment of advanced non-small cell lung cancer
Tuesday, August 27, 20242:15 PM – 2:30 PM CEST